Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Sena LA, et al. Among authors: ashkar r. Oncologist. 2021 Feb;26(2):e270-e278. doi: 10.1002/onco.13601. Epub 2020 Dec 3. Oncologist. 2021. PMID: 33215787 Free PMC article.
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, Perkins SM, Snow CI, Lazzara KM, Sego LM, Quinn DI, Hanna NH, Einhorn LH, Albany C. Ashkar R, et al. Invest New Drugs. 2021 Dec;39(6):1656-1663. doi: 10.1007/s10637-021-01134-1. Epub 2021 May 24. Invest New Drugs. 2021. PMID: 34031784 Free PMC article. Clinical Trial.
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Taza F, et al. Among authors: ashkar r. JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778690 Free PMC article.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Su CT, et al. Among authors: ashkar r. Prostate. 2023 Feb;83(3):227-236. doi: 10.1002/pros.24454. Epub 2022 Nov 16. Prostate. 2023. PMID: 36382533 Free PMC article.
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.
Richardson NH, Althouse SK, Ashkar R, Cary C, Masterson T, Foster RS, Einhorn LH, Adra N. Richardson NH, et al. Among authors: ashkar r. Clin Genitourin Cancer. 2023 Aug;21(4):467-474. doi: 10.1016/j.clgc.2023.03.018. Epub 2023 Apr 5. Clin Genitourin Cancer. 2023. PMID: 37088659
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: ashkar r. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760
53 results